Centenary welcomes approval of new hepatitis C drug

Professor Geoff McCaughan, Head of the Liver Immunobiology Group

Professor Geoff McCaughan, Head of Centenary's Liver Immunobiology Group

The Therapeutic Goods Administration has approved the hepatitis C medication, Victrelis. There are about 217,000 Australians living with chronic hepatitis C. Victrelis has been found to be suitable for the treatment of 40 per cent of patients. Unlike hepatitis A and B, there is no vaccine, making better treatments more important.

The Head of the Centenary Institute’s liver unit, Professor Geoff McCaughan, says the approval is a major breakthrough for patients.

“We’ve never had drugs aimed directly at the hepatitis C virus,” Professor McCaughan says.

You can read more about Centenary’s research into liver disease here.

To meet some of the Centenary researchers who work in the area of liver immunobiology, please click here.

Have you subscribed to our updates? Subscribe via RSS feed or enter your email address in the subscribe box.